Thymosin Alpha-1 — the immune modulator the US never approved but 35 countries did

The immune system's complexity was only beginning to come into focus in those years. The field didn't yet have the vocabulary it would later develop — T cells, cytokines, immunological memory as a mechanistic concept — and the idea that the thymus was an active regulator of immune identity rather than a passive developmental structure was not yet consensus. Goldstein's bet was that the thymus was secreting something. A hormone, or something like one. Something that could be isolated, characterized, and eventually used.

It took nearly a decade to find it.

Goldstein and his team began by grinding up bovine thymus tissue — working with calf thymus, which was abundant and biochemically similar to human tissue in the relevant ways — and fractionating the resulting extract through a series of increasingly refined separation steps. What they eventually isolated, in the early 1970s, was a complex mixture they called Thymosin Fraction 5. It was not a single compound. It was a soup. But it was a soup that, when injected into immune-deficient animals, appeared to restore immune function in measurable ways — increasing T-cell activity, improving the response to antigens, partially repairing the immune incompetence that followed thymus removal. The initial results were published and noticed.

The next task was to figure out what in the fraction was doing the work.

Over the following years, researchers began pulling individual components out of Thymosin Fraction 5. Several were identified and named: Thymosin Beta-4, which would later attract its own considerable research interest in tissue repair; Thymosin Beta-10; and, eventually, the component that would prove most clinically consequential — Thymosin Alpha-1. Tα1, as it came to be abbreviated, was a 28-amino-acid peptide. Short, stable, and highly conserved — meaning its sequence had remained nearly identical across species over evolutionary time, which is biology's way of flagging something as important. When you find a molecule that evolution hasn't changed, it usually means changing it breaks something.

The early research on Tα1 established a profile that was genuinely unusual in the pharmacology of immune compounds. It didn't behave like an immunosuppressant. It didn't behave like a simple immune stimulant either. What it appeared to do — and this would become the central, complicated claim about Tα1 for the next five decades — was modulate immune function in a context-dependent way. In immune-deficient animals, it appeared to restore activity. In contexts of dysregulated immune response, it appeared to normalize. The word "modulate" would come to do a lot of work in the Tα1 literature, sometimes honestly and sometimes as a way of avoiding harder questions about what the compound was actually doing and when.

From Goldstein's lab, the research moved into clinical territory. The 1980s and 1990s brought trials in human subjects. Chronic hepatitis B was among the first serious indications pursued. Hepatitis B is a viral infection that the immune system, in chronic carriers, has failed to clear — the virus persists not because it's inherently unclearable but because the immune system has reached a kind of exhausted standoff with it. The idea behind using Tα1 in this context was to break the standoff by restoring the immune response's capacity to act. Phase II and Phase III trials were conducted in Italy, in China, in the Philippines, and in other countries where hepatitis B burden was high and where regulatory agencies were receptive to innovative immune-based therapies.

The results were mixed — as clinical results usually are — but sufficiently consistent that several countries moved toward approval. Italy approved Thymosin Alpha-1 under the brand name Zadaxin, manufactured by SciClone Pharmaceuticals, for the treatment of chronic hepatitis B. China approved it, as did the Philippines, Singapore, and eventually more than 35 countries in total, spanning Europe, Asia, and parts of South America. The approved indications varied by country but consistently included chronic viral hepatitis, with adjuvant indications for cancer treatment and immune support in immunocompromised patients appearing in some markets. By the early 2000s, Zadaxin was being used widely in international clinical practice, particularly in Asia, where hepatitis B prevalence made the clinical need acute and where the regulatory environment had accommodated the evidence base.

The United States followed a different path. The FDA's Phase III requirements in the late 1990s and early 2000s were stringent by design — the agency had learned, repeatedly and painfully, what inadequate clinical trial design produced — and the trials that had been sufficient for approval in Italy and China did not meet the standard for US market authorization. The specific criticism was not that the data showed the drug didn't work. It was that the trial designs, particularly the randomization, blinding, and endpoint selection in the hepatitis B trials, fell short of what the FDA required to establish efficacy with the level of confidence it demanded.

SciClone pursued FDA approval through the late 1990s and into the early 2000s. The company ran US trials. The results were insufficient, and the FDA application did not succeed. Tα1 never achieved FDA approval in the United States for any indication.

This created a situation that has persisted for more than two decades and that explains the particular landscape Tα1 occupies in the US today. Internationally, it is an approved pharmaceutical, a known entity with a manufacturing standard and a regulatory home. In the United States, it is a compounded peptide — available through licensed compounding pharmacies when prescribed by a provider, but without the FDA approval that would place it in the mainstream pharmaceutical category. The same compound, with a substantial international clinical record, occupies the approved-drug tier in dozens of countries and the compounded-and-unapproved tier in the country with the world's largest and most influential regulatory apparatus.

The divergence is worth understanding clearly, because it's not simply a story of one country being more permissive or more cautious. The regulatory systems in Italy, China, and the US are genuinely different in how they weight different kinds of evidence, how they set the threshold for approval in disease areas where need is high and alternatives are limited, and how they handle compounds where the biological mechanism is well-characterized but the clinical evidence base was built through trials that don't perfectly mirror their preferred design standards. The FDA approval standard is, among other things, an economic threshold: it takes substantial investment to run US-qualifying Phase III trials, and by the early 2000s, the global market for Tα1 in hepatitis had been substantially reshaped by the emergence of nucleoside analogues — Lamivudine, and eventually the more potent tenofovir and entecavir — that offered simpler, more effective viral suppression and left less space for an immune-modulator approach. The commercial incentive to fund the US trial had eroded.

None of this tells you whether Tα1 works. What it tells you is that the regulatory record is not a clean read on the scientific evidence, and that the absence of FDA approval reflects a set of clinical, economic, and regulatory circumstances as much as it reflects an absence of underlying data. Goldstein himself continued research into thymosin peptides for the rest of his career, and the Tα1 literature has continued to accumulate in international publications, including a significant body of COVID-19-era research from Italy and China. The compound is one of the best-studied peptides in the immune modulation literature. It also has no US approval. Both things are true.

What the story of Thymosin Alpha-1 reveals, more broadly, is the degree to which the availability of a compound in clinical practice is a function of regulatory pathway, market economics, and trial-design standards as much as it is a function of the underlying evidence. The researchers who isolated Tα1 from bovine thymus tissue in the 1970s were working on a real biological question with real biological tools, and the compound they found has been used in clinical practice on multiple continents for decades. The gap between that record and FDA approval is not a gap in the science. It's a gap in the regulatory and commercial conditions that convert science into approved medicine in one particular country — and understanding that gap is a prerequisite for making sense of anything that follows in the Tα1 story.